Skip to nav Skip to content
David  Sallman

David Sallman, MD

4.9 (169)

Specialty: Hematology/Oncology

Program: Malignant Hematology

Language(s): English

  • Overview

    Cancer Focus:
    Leukemia, Myelodysplastic Syndromes (MDS)

    Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), based on the underlying mutational drivers of each disease.

    Education & Training

    Board Certification:

    • Internal Medicine - Medical Oncology

    Fellowship:

    • H. Lee Moffitt Cancer Center and Research Institute - Hematology/Oncology

    Residency:

    • Massachusetts General Hospital - Internal Medicine

    Medical School:

    • University of South Florida - MD
  • Participating Trials

    Clinical Trial 19481
    Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (Allogeneic Engineered T Cells Expressing anti-CD123 Chimeric Antigen Receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Condition: Malignant Hematology
    Intervention: Alemtuzumab (); Campath (Alemtuzumab); Elitek (Rasburicase); Hydroxyurea (Droxia); Rasburicase (); Rituxan (rituximab); Tocilizumab (); UCART123v1 (); UCART123v1.2 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); rituximab ()
    Status: Open

    Clinical Trial 19658
    A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
    Condition: Malignant Hematology
    Intervention: Cedazuridine (); SX-682 (); decitabine (5-aza-2'-deoxycytidine)
    Status: Open

    Clinical Trial 19862
    A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
    Condition: Malignant Hematology
    Intervention: PRGN-3006 T Cell (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
    Status: Open

    Clinical Trial 20552
    A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) who have Failed Erythropoietin Stimulating Agents (ESA)
    Condition: Malignant Hematology
    Intervention: Canakinumab (); Darbepoetin alfa ()
    Status: Open

    Clinical Trial 20749
    A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
    Condition: Malignant Hematology
    Intervention: CA-4948 (); GDC-0199 (Venetoclax); Venetoclax (); azacitidine (5-azacitidine)
    Status: Open

    Clinical Trial 21778
    An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Condition: Malignant Hematology
    Intervention: GDC-0199 (Venetoclax); SL-172154 (); Venetoclax (); azacitidine (5-azacitidine)
    Status: Open

    Clinical Trial 23059
    A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
    Condition: Malignant Hematology
    Intervention: Tamibarotene/Placebo (); azacitidine (5-azacitidine)
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Mar. Pubmedid: 38548563.
    • Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: 38170740. Pmcid: PMC10907389.
    • Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024 Jan.103(1):117-123. Pubmedid: 38030891.
    • Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024 Feb. Pubmedid: 38299605.
    • Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Feb. Pubmedid: 38429222.
    • Komrokji RS, Sengupta N, Supina D, Navada S, Potluri R, Tyagi R, Werwath T, Xie Z, Padron E, Sallman D. HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data. J Natl Compr Canc Ne. 2024 Apr.22(2.5). Pubmedid: 38579755.
    • Rajakumaraswamy N, Gandhi M, Wei AH, Sallman DA, Daver NG, Mo S, Iqbal S, Karalliyadda R, Chen M, Wang Y, Vyas P. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2024 Apr.24(4):260-268.e2. Pubmedid: 38216397.
    • Rollison DE, Gonzalez BD, Turner K, Jim HSL, Zhao Y, Amorrortu RP, Howard R, Ghia KM, Ngo B, Reisman P, Moore C, Perkins R, Keenan RJ, Sallman DA, Naso CM, Robinson EJ, Vadaparampil ST, Simmons VN, Schabath MB, Gilbert SM. Examining disparities in large-scale patient-reported data capture using digital tools among cancer patients at clinical intake. Cancer Med. 2023 Sep.12(18):19033-19046. Pubmedid: 37596773. Pmcid: PMC10557830.
    • Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet JE, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):e315-e322. Pubmedid: 37558530.
    • Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Nov.41(31):4893-4904. Pubmedid: 37703506. Pmcid: PMC10617926.
    • Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 Nov.62:101128. Pubmedid: 37704469.
    • Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 May.41(15):2815-2826. Pubmedid: 36888930.
    • Aguirre LE, Sallman DA, Stone R, Komrokji RS. Updates in Risk Stratification in Myelodysplastic Syndromes. Cancer J. 2023 May.29(3):138-142. Pubmedid: 37195769.
    • Tinsley-Vance SM, Ali NA, Ball S, Aguirre LE, Jain AG, Hussaini MO, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman DA, Komrokji RS. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clin Lymphoma Myeloma Leuk. 2023 May.23(5):355-359. Pubmedid: 36813626. Pmcid: PMC10121764.
    • Mo Q, Yun S, Sallman DA, Vincelette ND, Peng G, Zhang L, Lancet JE, Padron E. Integrative molecular subtypes of acute myeloid leukemia. Blood Cancer J. 2023 May.13(1):71. Pubmedid: 37156780. Pmcid: PMC10167212.
    • Wang C, Sallman DA. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. CURR TREAT OPTION ON. 2023 May.24(5):387-408. Pubmedid: 36966266.
    • Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
    • Wang C, Sallman DA. Therapeutic approaches for the management of higher risk myelodysplastic syndromes. Leuk Lymphoma. 2023 Mar.64(3):511-524. Pubmedid: 36433645.
    • Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023 Mar.10(3):e191-e202. Pubmedid: 36764323.
    • Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Adv. 2023 Jun.7(12):2709-2714. Pubmedid: 36260702. Pmcid: PMC10333740.
    • Komrokji RS, Aguirre LE, Al-Ali N, Chan O, Xie Z, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Sallman DA. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv. 2023 Jul.7(14):3677-3679. Pubmedid: 37058483. Pmcid: PMC10365940.
    • Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, Tinsley-Vance SM, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023 Jul.37(7):1530-1539. Pubmedid: 37147425.
    • Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023 Jul.60:101072. Pubmedid: 36934059.
    • Komrokji RS, Aguirre LE, Al-Ali N, Hussaini MO, Sallman DA, Rollison DE, Padron E. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Adv. 2023 Jan.7(1):1-8. Pubmedid: 36129843. Pmcid: PMC9813529.
    • Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 2023 Jan.129(2):175-180. Pubmedid: 36397669.
    • Boucher JC, Yu B, Li G, Shrestha B, Sallman D, Landin AM, Cox C, Karyampudi K, Anasetti C, Davila ML, Bejanyan N. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. J Immunother. 2023 Jan.46(1):5-13. Pubmedid: 36378147. Pmcid: PMC9722378.
    • Ball S, Aguirre LE, Jain AG, Ali NA, Tinsley SM, Chan O, Kuykendall AT, Sweet K, Lancet JE, Sallman DA, Hussaini MO, Padron E, Komrokji RS. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leuk Res. 2023 Jan.124:106999. Pubmedid: 36542963.
    • Hasegawa K, Wei AH, Garcia-Manero G, Daver NG, Rajakumaraswamy N, Iqbal S, Chan RJ, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Sallman DA. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2023 Feb.23(2):127-137. Pubmedid: 36428152.
    • Subklewe M, Bücklein V, Sallman D, Daver N. Novel immunotherapies in the treatment of AML: is there hope?. Hematology Am Soc Hematol Educ Program. 2023 Dec.2023(1):691-701. Pubmedid: 38066884. Pmcid: PMC10727092.
    • Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023 Dec.98(12):E360-E363. Pubmedid: 37705256.
    • Sallman DA, Xie Z. Frontline treatment options for higher-risk MDS: can we move past azacitidine?. Hematology Am Soc Hematol Educ Program. 2023 Dec.2023(1):65-72. Pubmedid: 38066872. Pmcid: PMC10727006.
    • Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. Clin Cancer Res. 2023 Aug.29(15):2919-2932. Pubmedid: 37223910. Pmcid: PMC10524644.
    • Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia. 2023 Aug.37(8):1753-1756. Pubmedid: 37422593.
    • Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 Apr.98(4):E76-E79. Pubmedid: 36655582.
    • Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr.10(4):e272-e283. Pubmedid: 36990622.
    • Komrokji R, Al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica. 2023 Apr.108(4):1168-1172. Pubmedid: 36420802. Pmcid: PMC10071110.
    • Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 Sep.3(5):385-393. Pubmedid: 35533245. Pmcid: PMC9445749.
    • Fujihara KM, Zhang BZ, Jackson TD, Ogunkola MO, Nijagal B, Milne JV, Sallman DA, Ang CS, Nikolic I, Kearney CJ, Hogg SJ, Cabalag CS, Sutton VR, Watt S, Fujihara AT, Trapani JA, Simpson KJ, Stojanovski D, Leimkühler S, Haupt S, Phillips WA, Clemons NJ. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci Adv. 2022 Sep.8(37):eabm9427. Pubmedid: 36103522. Pmcid: PMC9473576.
    • Radakovich N, Sallman DA, Buckstein R, Brunner A, Dezern A, Mukerjee S, Komrokji R, Al-Ali N, Shreve J, Rouphail Y, Parmentier A, Mamedov A, Siddiqui M, Guan Y, Kuzmanovic T, Hasipek M, Jha B, Maciejewski JP, Sekeres MA, Nazha A. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. iScience. 2022 Oct.25(10):104931. Pubmedid: 36157589. Pmcid: PMC9490588.
    • Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: 35942592.
    • Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, Kuykendall A, Komrokji R, Lancet J, Sallman D, Talati C, Sweet K. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):774-779. Pubmedid: 35760672.
    • Komrokji RS, Singh AM, Ali NA, Chan O, Padron E, Sweet K, Kuykendall A, Lancet JE, Sallman DA. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022 Nov.12(11):148. Pubmedid: 36329025. Pmcid: PMC9633639.
    • Ferrall-Fairbanks MC, Dhawan A, Johnson B, Newman H, Volpe V, Letson C, Ball M, Hunter AM, Balasis ME, Kruer T, Ben-Crentsil NA, Kroeger JL, Balderas R, Komrokji RS, Sallman DA, Zhang J, Bejar R, Altrock PM, Padron E. Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discov. 2022 Nov.3(6):536-553. Pubmedid: 36053528. Pmcid: PMC9627238.
    • Brunner AM, Gavralidis A, Ali NA, Hunter A, Komrokji R, Zeidan A, Sallman DA. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer J. 2022 Nov.12(11):153. Pubmedid: 36379923. Pmcid: PMC9666661.
    • Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, Chan O, Hussaini MO, Zhang L, Sweet KL, Kuykendall AT, Talati C, Padron E, Komrokji RS, Lancet JE, Sallman DA. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Nov.128(21):3880-3887. Pubmedid: 36107670.
    • Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 Nov.12(11):2516-2529. Pubmedid: 36218325. Pmcid: PMC9627130.
    • Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Ali NHA, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May.107(5):1189-1192. Pubmedid: 35142154. Pmcid: PMC9052897.
    • Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: 35179241.
    • Sallman DA, Bejar R, Montalban-Bravo G, Kurtin SE, List AF, Garcia-Manero G, Nimer SD, O'Connell CL, Schaar D, Butchko J, Iraca T, Searle S. Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning. Leuk Res Rep. 2022 May.17:100328. Pubmedid: 35663282. Pmcid: PMC9160489.
    • Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. 2022 Mar.107(3):737-739. Pubmedid: 34320786. Pmcid: PMC8883562.
    • Ball S, Komrokji RS, Sallman DA. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile. Leuk Lymphoma. 2022 Jun.63(6):1281-1291. Pubmedid: 34933652.
    • Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e521-e525. Pubmedid: 35241387.
    • Chan O, Ali NA, Sallman D, Padron E, Lancet J, Komrokji R. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e467-e476. Pubmedid: 35101379.
    • Wang C, Sallman DA. Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies. Curr Opin Hematol. 2022 Jan.29(1):44-52. Pubmedid: 34854834.
    • Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, Sekeres MA, Lucas G, Maciejewski JP, Sallman DA, Padron E, Kuykendall A, Lasho T, Al-Kali A, Naqvi K, Steensma DP, Garcia-Manero G, Patnaik MM. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 Jan.63(1):199-204. Pubmedid: 34448437.
    • Wang C, Sallman DA. What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?. Cancer J. 2022 Jan.28(1):51-61. Pubmedid: 35072374.
    • Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Ne. 2022 Feb.20(2):106-117. Pubmedid: 35130502.
    • Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb.12(2):26. Pubmedid: 35105856. Pmcid: PMC8807827.
    • Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Dec.36(12):2939-2946. Pubmedid: 36266326.
    • Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022 Dec.40(34):3985-3993. Pubmedid: 35816664.
    • Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 Dec.36(12):2934-2938. Pubmedid: 36335264.
    • Volpe VO, Al Ali N, Chan O, Padron E, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Komrokji RS. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. Brit J Haematol. 2022 Aug.198(4):713-720. Pubmedid: 35751140.
    • McLemore AF, Hou HA, Meyer BS, Lam NB, Ward GA, Aldrich AL, Rodrigues MA, Vedder A, Zhang L, Padron E, Vincelette ND, Sallman DA, Abdel-Wahab O, List AF, McGraw KL. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI Insight. 2022 Aug.7(15). Pubmedid: 35788117. Pmcid: PMC9462508.
    • Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 Apr.36(4):1189-1192. Pubmedid: 34975158.
    • Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, Padron E, Sallman DA. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes. Blood. 2021 Sep.138(11):989-992. Pubmedid: 34036300.
    • Cluzeau T, Loschi M, Fenaux P, Komrokji R, Sallman DA. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Int J Mol Sci. 2021 Sep.22(18). Pubmedid: 34576266. Pmcid: PMC8471083.
    • Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Oct.109:106640. Pubmedid: 34144312.
    • Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2021 Nov.27(22):6095-6105. Pubmedid: 34253584. Pmcid: PMC8595542.
    • Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021 Nov.39(33):3737-3746. Pubmedid: 34406850. Pmcid: PMC8601291.
    • Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leuk Lymphoma. 2021 Nov.62(11):2762-2767. Pubmedid: 34114922.
    • Sallman DA, Ball S. Expanding the immune armoury against myelodysplastic syndrome. Brit J Haematol. 2021 Nov.195(3):301-303. Pubmedid: 34340253.
    • Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: 33449813. Pmcid: PMC8099410.
    • Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021 May.39(14):1575-1583. Pubmedid: 33600210. Pmcid: PMC8099409.
    • Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 May.21(5):e483-e487. Pubmedid: 33551344.
    • Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 Mar.11(3):52. Pubmedid: 33677472. Pmcid: PMC7936977.
    • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
    • Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: 33583730.
    • Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: 33132383.
    • Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: 33093008.
    • Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021 Jan.10(2):447-453. Pubmedid: 33350168. Pmcid: PMC7877342.
    • Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: 33591325. Pmcid: PMC7903224.
    • Song A, Altabbakh O, Sallman DA, Padron E, Talati C, Hussaini MO. Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes. Eur J Haematol. 2021 Dec.107(6):609-616. Pubmedid: 34407254.
    • Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: 34749168. Pmcid: PMC8643343.
    • Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: 34029507.
    • Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J, Esparza S, Hussaini MO, Van Deventer H, Foster MC, Coombs CC, Montgomery ND, Sallman DA, Zeidner JF. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. Am J Hematol. 2021 Apr.96(4):462-470. Pubmedid: 33502020.
    • Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: 32728186. Pmcid: PMC7854836.
    • Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 Sep.20(9):e597-e605. Pubmedid: 32303488.
    • Sallman DA. The Problem of TP53-Mutant MDS/AML. Clin Lymphoma Myeloma Leuk. 2020 Sep.20 Suppl 1:S65-S66. Pubmedid: 32862873.
    • Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: 32565544.
    • Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):324-328. Pubmedid: 32044274.
    • Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Eur J Haematol. 2020 May.104(5):488-498. Pubmedid: 31990086.
    • Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):312-315. Pubmedid: 32139296.
    • Swoboda DM, Gesiotto Q, Sallman DA. Novel therapies in myelodysplastic syndromes. Curr Opin Hematol. 2020 Mar.27(2):58-65. Pubmedid: 31972686.
    • Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leuk Lymphoma. 2020 Jun.61(6):1395-1405. Pubmedid: 32091281. Pmcid: PMC7269833.
    • Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun.93:106367. Pubmedid: 32408060. Pmcid: PMC7771257.
    • Badar T, Szabo A, Sallman D, Komrokji R, Lancet J, Padron E, Song J, Hussaini MO. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020 Jun.61(6):1418-1427. Pubmedid: 32013644.
    • Sallman DA. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2020 Jun.105(6):1470-1472. Pubmedid: 32482751. Pmcid: PMC7271586.
    • Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres M, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase DT, Tuechler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg ES, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020 Jul.136(2):157-170. Pubmedid: 32347921. Pmcid: PMC7362582.
    • Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020 Jul.4(13):2866-2870. Pubmedid: 32589727. Pmcid: PMC7362378.
    • Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jan.26(1):54-60. Pubmedid: 31636097. Pmcid: PMC7787346.
    • Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: 32730593. Pmcid: PMC7731792.
    • Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: 32778513.
    • Swoboda DM, Sallman DA. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies. Best Pract Res Clin Haematol. 2020 Dec.33(4):101221. Pubmedid: 33279177.
    • Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leuk Lymphoma. 2020 Aug.61(8):1901-1907. Pubmedid: 32306798.
    • Patnaik MM, Sallman DA, Mangaonkar A, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug.136(7):909-913. Pubmedid: 32294158. Pmcid: PMC7531999.
    • Badaat I, Mirza S, Padron E, Sallman D, Komrokji R, Song J, Hussaini MO. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. J Clin Pathol. 2020 Apr.73(4):209-212. Pubmedid: 31771970.
    • Hunter AM, Sallman DA. Targeting TP53 Mutations in Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020 Apr.34(2):421-440. Pubmedid: 32089220.
    • Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: 31357093. Pmcid: PMC7375354.
    • McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019 Nov.3(22):3579-3589. Pubmedid: 31738830. Pmcid: PMC6880887.
    • Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar.19(3):157-161. Pubmedid: 30713125.
    • Lee JH, List A, Sallman DA. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol. 2019 Mar.102(3):203-209. Pubmedid: 30578738.
    • Chung J, Sallman DA, Padron E. TP53 and therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2019 Mar.32(1):98-103. Pubmedid: 30927980.
    • Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019 Mar.133(10):1039-1048. Pubmedid: 30670444. Pmcid: PMC7022316.
    • Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019 Jun.81:56-61. Pubmedid: 31030089. Pmcid: PMC7787349.
    • Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Tr. 2019 Jun.25(6):1142-1151. Pubmedid: 30625392. Pmcid: PMC6918823.
    • Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019 Jun.32(2):134-144. Pubmedid: 31203995.
    • Sallman DA, List A. The role of innate immunity in MDS pathogenesis. Hemasphere. 2019 Jun.3(Suppl). Pubmedid: 35309825. Pmcid: PMC8925693.
    • Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 Jul.33(7):1747-1758. Pubmedid: 30635634. Pmcid: PMC6609480.
    • Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: 30390311.
    • McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Brit J Haematol. 2019 Feb.184(3):450-455. Pubmedid: 29359794. Pmcid: PMC7771337.
    • Swoboda DM, Sallman DA. Mutation-Driven Therapy in MDS. Curr Hematol Malig Rep. 2019 Dec.14(6):550-560. Pubmedid: 31760573.
    • Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec.94(12):E314-E317. Pubmedid: 31444809.
    • Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia. 2019 Aug.33(8):2034-2046. Pubmedid: 30737486. Pmcid: PMC6687540.
    • Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr.19(4):251-254. Pubmedid: 30852241.
    • Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018 Sep.103(9):e424-e426. Pubmedid: 29703727. Pmcid: PMC6119132.
    • Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018 Sep.5(9):e393-e402. Pubmedid: 30072146. Pmcid: PMC6505461.
    • Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 Oct.93(10):1245-1253. Pubmedid: 30051599. Pmcid: PMC6750209.
    • Talati C, Sallman D, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clin Lymphoma Myeloma Leuk. 2018 Oct.18(10):629-635. Pubmedid: 30097406.
    • Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018 May.31:174-181. Pubmedid: 29728305. Pmcid: PMC6013781.
    • Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: 29189896.
    • Sallman DA, Tanaka TN, List A, Bejar R. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2017 Oct.17(10):613-620. Pubmedid: 29025689.
    • Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: 28687222. Pmcid: PMC5675815.
    • Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017 Nov.7(11):e017075. Pubmedid: 29133316. Pmcid: PMC5695348.
    • Sallman DA, Lancet JE. What are the most promising new agents in acute myeloid leukemia?. Curr Opin Hematol. 2017 Mar.24(2):99-107. Pubmedid: 28030373.
    • Sallman DA, Davila ML. Is Disease-Specific Immunotherapy a Potential Reality for MDS?. Clin Lymphoma Myeloma Leuk. 2017 Jul.17S:S26-S30. Pubmedid: 28760299.
    • Talati C, Sallman D, List A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Semin Hematol. 2017 Jul.54(3):159-166. Pubmedid: 28958290.
    • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan.18(1):112-121. Pubmedid: 27927582. Pmcid: PMC7771361.
    • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: 28869184.
    • Zhang L, McGraw KL, Sallman DA, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma. 2017 Aug.58(8):1777-1790. Pubmedid: 27967292.
    • Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017 11.7(12):633. Pubmedid: 29176559. Pmcid: PMC5802523.
    • Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 03.31(3):767-768. Pubmedid: 27740632.
    • Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016 Sep.9(3):89-95. Pubmedid: 27187622.
    • Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016 Sep.13(3):360-372. Pubmedid: 27807503. Pmcid: PMC5069836.
    • Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov.101(11):e457-e460. Pubmedid: 27418649. Pmcid: PMC5394875.
    • Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar.30(3):666-673. Pubmedid: 26514544. Pmcid: PMC7864381.
    • Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. 2016 Jun.6:151. Pubmedid: 27379212. Pmcid: PMC4909736.
    • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec.128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
    • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug.101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
    • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct.6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
    • Sallman DA, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S50-S55. Pubmedid: 26297278.
    • Sallman DA, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion. Front Oncol. 2014 Sep.4:264. Pubmedid: 25295231. Pmcid: PMC4172014.
    • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb.32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
    • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr.113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
    • Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, Djeu JY. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther. 2007 Nov.6(11):2938-2947. Pubmedid: 18025278.
    • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006 Oct.25(45):6113-6122. Pubmedid: 16652143.
  • Grants

    Title: Phase 1-Open-Label-Dose-Escal w Expansion Study-SX-682 in Subjects w Myelodysplastic Syndrome w Disease Progression or Intolerant to Prior Therapy
    Sponsor: Syntrix Pharmaceuticals
    PI: Sallman, D.
    Title: Gene Expression Profiling to Investigate Drivers of Response and Resistance to Gilteritinib-based Combination Therapy in FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
    Sponsor: Amer Society of Clinical Oncology (ASCO)
    PI: Sallman, D.
  • Patient Comments

    Overall Satisfaction

    4.9

    169 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor